John H Stone, ACR 2020: Tocilizumab for COVID-19 Infection
Access all of the content
It was a pleasure to be able to speak with John Stone (Massachusetts General Hospital, Boston, MA, USA) about the findings from his investigations into tocilizumab as a therapy for COVID-19 infection.
His presentation entitled ‘Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial’ (Abstract Number: L07) was presented at the ACR Convergence, 5-9 November.
- What is the rationale for the use of tocilizumab for COVID-19 infection? (0:16)
- What is the rationale for the use of tocilizumab for COVID-19 infection? (1:40)
- What might explain tocilizumab’s lack of efficacy in this treatment setting? (3:07)
- How do these findings compare with other studies of tocilizumab for COVID-19 infection? (4:32)
- Is tocilizumab likely to play any role in the treatment of COVID-19 outcomes? (5:20)
Disclosures: John H. Stone has received research funding from Roche, Principia, Viela Bio and Bristol Myers Squibb; and consulting fees from Roche, Principia, Viela Bio, Bristol Myers Squibb, Sanofi, Chemocentryx, Celgene, Abbvie, Chugai, Grunenthal, Glaxo Smith Kline, Infla Rx, Insmed, Regeneron, Roivant, Q32 bio, and SpruceBiosciences.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In COVID-19
Alessio Cortellini, ESMO Immuno-Oncology 2022: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer
A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. In this touchIMMUNOLOGY interview, we spoke with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!